489 related articles for article (PubMed ID: 28604704)
21. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.
Pejnovic N; Jeftic I; Jovicic N; Arsenijevic N; Lukic ML
World J Gastroenterol; 2016 Nov; 22(44):9706-9717. PubMed ID: 27956794
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis.
Chiu CC; Ching YH; Li YP; Liu JY; Huang YT; Huang YW; Yang SS; Huang WC; Chuang HL
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29113135
[TBL] [Abstract][Full Text] [Related]
23. Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD.
Gehrke N; Biedenbach J; Huber Y; Straub BK; Galle PR; Simon P; Schattenberg JM
Sci Rep; 2019 Mar; 9(1):4007. PubMed ID: 30850619
[TBL] [Abstract][Full Text] [Related]
24. NKT cell modulates NAFLD potentiation of metabolic oxidative stress-induced mesangial cell activation and proximal tubular toxicity.
Alhasson F; Dattaroy D; Das S; Chandrashekaran V; Seth RK; Schnellmann RG; Chatterjee S
Am J Physiol Renal Physiol; 2016 Jan; 310(1):F85-F101. PubMed ID: 26447219
[TBL] [Abstract][Full Text] [Related]
25. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
Wang P; Wang J; Li D; Ke W; Chen F; Hu X
J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
[TBL] [Abstract][Full Text] [Related]
26. Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.
Yu S; Jiang J; Li Q; Liu X; Wang Z; Yang L; Ding L
Front Cell Infect Microbiol; 2022; 12():855008. PubMed ID: 36132991
[TBL] [Abstract][Full Text] [Related]
27. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
[TBL] [Abstract][Full Text] [Related]
28. Blocking integrin α
Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
[TBL] [Abstract][Full Text] [Related]
29. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
30. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity.
Hartmann P; Seebauer CT; Mazagova M; Horvath A; Wang L; Llorente C; Varki NM; Brandl K; Ho SB; Schnabl B
Am J Physiol Gastrointest Liver Physiol; 2016 Mar; 310(5):G310-22. PubMed ID: 26702135
[TBL] [Abstract][Full Text] [Related]
31. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
[TBL] [Abstract][Full Text] [Related]
32. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
[TBL] [Abstract][Full Text] [Related]
34. Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis.
Giles DA; Moreno-Fernandez ME; Stankiewicz TE; Cappelletti M; Huppert SS; Iwakura Y; Dong C; Shanmukhappa SK; Divanovic S
PLoS One; 2016; 11(2):e0149783. PubMed ID: 26895034
[TBL] [Abstract][Full Text] [Related]
35. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
36. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease.
Baumann A; Nier A; Hernández-Arriaga A; Brandt A; Lorenzo Pisarello MJ; Jin CJ; Pilar E; Camarinha-Silva A; Schattenberg JM; Bergheim I
Sci Rep; 2021 Sep; 11(1):17815. PubMed ID: 34497333
[TBL] [Abstract][Full Text] [Related]
37. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
38. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
[TBL] [Abstract][Full Text] [Related]
39. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
[TBL] [Abstract][Full Text] [Related]
40. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
